174 related articles for article (PubMed ID: 7509441)
1. The species selectivity of chemically distinct tachykinin nonpeptide antagonists is dependent on common divergent residues of the rat and human neurokinin-1 receptors.
Jensen CJ; Gerard NP; Schwartz TW; Gether U
Mol Pharmacol; 1994 Feb; 45(2):294-9. PubMed ID: 7509441
[TBL] [Abstract][Full Text] [Related]
2. Evidence for a common molecular mode of action for chemically distinct nonpeptide antagonists at the neurokinin-1 (substance P) receptor.
Gether U; Emonds-Alt X; Brelière JC; Fujii T; Hagiwara D; Pradier L; Garret C; Johansen TE; Schwartz TW
Mol Pharmacol; 1994 Mar; 45(3):500-8. PubMed ID: 8145735
[TBL] [Abstract][Full Text] [Related]
3. Two nonpeptide tachykinin antagonists act through epitopes on corresponding segments of the NK1 and NK2 receptors.
Gether U; Yokota Y; Emonds-Alt X; Brelière JC; Lowe JA; Snider RM; Nakanishi S; Schwartz TW
Proc Natl Acad Sci U S A; 1993 Jul; 90(13):6194-8. PubMed ID: 7687062
[TBL] [Abstract][Full Text] [Related]
4. Specific residues at the top of transmembrane segment V and VI of the neurokinin-1 receptor involved in binding of the nonpeptide antagonist CP 96,345 [corrected].
Gether U; Nilsson L; Lowe JA; Schwartz TW
J Biol Chem; 1994 Sep; 269(39):23959-64. PubMed ID: 7929043
[TBL] [Abstract][Full Text] [Related]
5. Relevance of aromatic residues in transmembrane segments V to VII for binding of peptide and nonpeptide antagonists to the human tachykinin NK(2) receptor.
Renzetti AR; Catalioto RM; Criscuoli M; Cucchi P; Ferrer C; Giolitti A; Guelfi M; Rotondaro L; Warner FJ; Maggi CA
J Pharmacol Exp Ther; 1999 Aug; 290(2):487-95. PubMed ID: 10411554
[TBL] [Abstract][Full Text] [Related]
6. Conserved HisVI-17 of the NK-1 receptor is involved in binding of non-peptide antagonists but not substance P.
Zoffmann S; Gether U; Schwartz TW
FEBS Lett; 1993 Dec; 336(3):506-10. PubMed ID: 7506676
[TBL] [Abstract][Full Text] [Related]
7. Molecular determinants of the species selectivity of neurokinin type 1 receptor antagonists.
Pradier L; Habert-Ortoli E; Emile L; Le Guern J; Loquet I; Bock MD; Clot J; Mercken L; Fardin V; Garret C
Mol Pharmacol; 1995 Feb; 47(2):314-21. PubMed ID: 7532784
[TBL] [Abstract][Full Text] [Related]
8. Steric hindrance mutagenesis versus alanine scan in mapping of ligand binding sites in the tachykinin NK1 receptor.
Holst B; Zoffmann S; Elling CE; Hjorth SA; Schwartz TW
Mol Pharmacol; 1998 Jan; 53(1):166-75. PubMed ID: 9443945
[TBL] [Abstract][Full Text] [Related]
9. Effect of YM-44781, YM-44778 and YM-49598, novel tachykinin antagonists, in a drug-induced bladder contraction model.
Choppin A; Groke G; Bringas A; Stepan G; Dillon MP
Pharmacology; 2002 May; 65(2):96-102. PubMed ID: 11937780
[TBL] [Abstract][Full Text] [Related]
10. Split-receptors in the tachykinin neurokinin-1 system--mutational analysis of intracellular loop 3.
Nielsen SM; Elling CE; Schwartz TW
Eur J Biochem; 1998 Jan; 251(1-2):217-26. PubMed ID: 9492287
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis for the species selectivity of the neurokinin-1 receptor antagonists CP-96,345 and RP67580.
Fong TM; Yu H; Strader CD
J Biol Chem; 1992 Dec; 267(36):25668-71. PubMed ID: 1281470
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of an original and selective nonpeptide antagonist ligand for the human tachykinin NK2 receptor.
Meini S; Catalani C; Bellucci F; Cucchi P; Giuliani S; Zappitelli S; Rotondaro L; Pasqui F; Guidi A; Altamura M; Giolitti A; Maggi CA
Eur J Pharmacol; 2005 Jun; 516(2):104-11. PubMed ID: 15925360
[TBL] [Abstract][Full Text] [Related]
13. Two related neurokinin-1 receptor antagonists have overlapping but different binding sites.
Greenfeder S; Cheewatrakoolpong B; Anthes J; Billah M; Egan RW; Brown JE; Murgolo NJ
Bioorg Med Chem; 1998 Feb; 6(2):189-94. PubMed ID: 9547942
[TBL] [Abstract][Full Text] [Related]
14. Interaction of glutamine 165 in the fourth transmembrane segment of the human neurokinin-1 receptor with quinuclidine antagonists.
Fong TM; Yu H; Cascieri MA; Underwood D; Swain CJ; Strader CD
J Biol Chem; 1994 May; 269(21):14957-61. PubMed ID: 8195129
[TBL] [Abstract][Full Text] [Related]
15. Mutations along transmembrane segment II of the NK-1 receptor affect substance P competition with non-peptide antagonists but not substance P binding.
Rosenkilde MM; Cahir M; Gether U; Hjorth SA; Schwartz TW
J Biol Chem; 1994 Nov; 269(45):28160-4. PubMed ID: 7525569
[TBL] [Abstract][Full Text] [Related]
16. Conversion of antagonist-binding site to metal-ion site in the tachykinin NK-1 receptor.
Elling CE; Nielsen SM; Schwartz TW
Nature; 1995 Mar; 374(6517):74-7. PubMed ID: 7532789
[TBL] [Abstract][Full Text] [Related]
17. Both extracellular and transmembrane residues contribute to the species selectivity of the neurokinin-1 receptor antagonist WIN 51708.
Sachais BS; Krause JE
Mol Pharmacol; 1994 Jul; 46(1):122-8. PubMed ID: 8058046
[TBL] [Abstract][Full Text] [Related]
18. The role of histidine 265 in antagonist binding to the neurokinin-1 receptor.
Fong TM; Yu H; Cascieri MA; Underwood D; Swain CJ; Strader CD
J Biol Chem; 1994 Jan; 269(4):2728-32. PubMed ID: 8300604
[TBL] [Abstract][Full Text] [Related]
19. Molecular determinants of peptide and nonpeptide NK-2 receptor antagonists binding sites of the human tachykinin NK-2 receptor by site-directed mutagenesis.
Giolitti A; Cucchi P; Renzetti AR; Rotondaro L; Zappitelli S; Maggi CA
Neuropharmacology; 2000 Jun; 39(8):1422-9. PubMed ID: 10818258
[TBL] [Abstract][Full Text] [Related]
20. Localization of the ligand binding site of the neurokinin-1 receptor: interpretation of chimeric mutations and single-residue substitutions.
Huang RR; Yu H; Strader CD; Fong TM
Mol Pharmacol; 1994 Apr; 45(4):690-5. PubMed ID: 8183248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
